Insider Cluster (3 insiders) ·Filed Jun 10, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago
Insider cluster: 3 insiders, $1.2M total
Actionable Insight • Neutral

Monitor upcoming quarterly earnings for any fundamental changes. The insider selling is too small to be actionable on its own.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
UTHR ▼ -10.64% at T+60d
NEUTRAL call ✗ call lost -10.64% · α vs SPY -15.04% · entry $545.40 → $487.35
Entry anchored
Jun 10, 03:59 PM ET
via exchange tick
T+1d
+0.10%
call +0.10% · α -0.44%
$545.96
settled 4mo ago
T+5d
+1.11%
call +1.11% · α +0.68%
$551.47
settled 4mo ago
T+20d
+1.30%
call +1.30% · α -0.59%
$552.48
settled 3mo ago
T+60d
-10.64%
call -10.64% · α -15.04%
$487.35
settled 28d ago

Price Chart

Loading chart...

Executive Summary

A small insider selling cluster at United Therapeutics (UTHR) saw the CEO, CFO, and EVP/GCO sell a combined ~$1.23M in open-market shares over a week, but this represents less than 0.01% of the company's $23.5B market cap. The sales follow option exercises and appear routine for tax withholding or liquidity. No material signal for traders.

Key Financial Metrics

Direction
selling
Total Value
$1.2M
Insiders
3

Key Facts

  • Three insiders sold ~$1.23M in open-market shares, 0.005% of market cap.
  • CEO Martine Rothblatt sold 491 shares ($267K), CFO James Edgemond sold 1,565 shares ($853K), EVP Paul Mahon sold 200 shares ($108K).
  • All sales occurred after exercising derivative securities, indicating routine tax-related or liquidity-driven transactions.
  • Open-market sales were a tiny fraction of the shares acquired via option exercises.
  • No significant insider buying or unusual pattern detected.

Financial Impact

Total insider sales of $1.23M, negligible relative to $23.5B market cap.

Risk Factors

  • Insider sales could precede negative news, but the scale here is minimal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1781124226769
91 reports for UTHR
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$500.35 $497.31▼ −0.61%▼ −2.72%$573.51 (+14.62%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$497.11 $494.63▼ −0.50%▼ −0.28%$573.51 (+15.37%)
Sep 10, 2026
22d ago
Insider Cluster
MIXED ★ 4/10
$503.86 $497.27▼ −1.31%▼ −0.81%$573.51 (+13.82%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$506.82 $498.48▼ −1.65%▼ −0.99%$573.51 (+13.16%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$487.61 $502.70▲ +3.09%▲ +4.30%$573.51 (+17.62%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$488.16 $497.11▲ +1.83%▲ +2.98%$573.51 (+17.48%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$515.46 $487.61▼ −5.40%▼ −5.51%$573.51 (+11.26%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$527.91 $492.02▼ −6.80%▼ −6.03%$573.51 (+8.64%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$516.68 $492.02▼ −4.77%▼ −4.65%$573.51 (+11.00%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$516.68 $492.02▼ −4.77%▼ −4.65%$573.51 (+11.00%)
Showing 10 of 91

US Market Status

Market Open — Closes in 6h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 10, 2026